Insurance Coverage for Continuous Glucose Monitors

Primary Coverage Landscape

The American College of Physicians recommends that both Dexcom G6/G7 and FreeStyle Libre systems have achieved broad insurance coverage, including Medicare eligibility, making them the most accessible options for patients requiring CGM technology 1

The FDA has approved the Dexcom G5/G6 systems for making treatment decisions without confirmatory blood glucose monitoring checks, which is a key factor in insurance coverage decisions, with a Grade A recommendation for real-time CGM in conjunction with intensive insulin regimens in adults with type 1 diabetes 1, 2
Factory-calibrated systems like Dexcom G6/G7 and FreeStyle Libre do not require fingerstick blood glucose calibrations, reducing overall monitoring costs, with evidence from the Endocrine Society 2, 3

Real-time CGM in conjunction with intensive insulin regimens lowers HbA1c levels in adults with type 1 diabetes, providing strong evidence for coverage, with a Grade A recommendation from the American Diabetes Association 1

The American Association of Clinical Endocrinologists recommends that patients with type 1 diabetes on insulin should use the Dexcom G6/G7 for real-time alerts and integration with insulin pumps, which is well-supported by insurance coverage 2, 4
Real-time CGM is particularly beneficial and covered for those with hypoglycemia unawareness or frequent hypoglycemic episodes, with a Grade B recommendation from the Endocrine Society 2, 4

The Centers for Medicare and Medicaid Services requires documentation that the CGM continuously measured glucose and displayed data in real-time >95% of the time for the duration specified in the product label, with comprehensive reports and validation of glucose values documented in electronic health records to support ongoing coverage 5
Alternative systems, such as the Senseonics Eversense implantable CGM, have FDA approval for use with automated insulin delivery systems but may have different coverage patterns due to the required minor surgical procedure for implantation, as noted by the American College of Surgeons 4

CGM systems are noted as "relatively expensive" in clinical guidelines, though specific dollar amounts vary by system, according to the American Diabetes Association 6, 7
Real-time CGM systems generally have higher direct costs than intermittently scanned CGM (flash monitoring) systems, as reported by the American Association of Clinical Endocrinologists 8

Coverage decisions should be based on thorough evaluation of patient characteristics, needs, and device availability through shared decision-making, as recommended by the American Diabetes Association 6, 7